Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tagmokitug

A human immunoglobulin G1 (IgG1) afucosylated monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, tagmokitug targets and binds to CCR8 on CCR8-positive tumor-infiltrating regulatory T cells (Tregs) in the tumor microenvironment (TME), and depletes CCR8-positive tumor-infiltrating Tregs via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). This may reactivate antitumor immune responses. CCR8 is specifically expressed by tumor-infiltrating Tregs in multiple types of cancer and plays a key role in immunosuppression.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CCR8 monoclonal antibody CHS-114
anti-CCR8 monoclonal antibody SRF114
Code name:CHS 114
CHS-114
CHS114
SRF 114
SRF-114
SRF114
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search